Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Microencapsulated CYP 2B1-expressing cells + ifosfamide - PharmaCyte Biotech

Drug Profile

Microencapsulated CYP 2B1-expressing cells + ifosfamide - PharmaCyte Biotech

Alternative Names: Breast cancer cell therapy - PharmaCyte Biotech; CYP-2B1-gene-therapy-PharmaCyte-Biotech; CypCaps; Cytochrome-P450-2B1-gene-therapy-PharmaCyte-Biotech; Encapsulated cyclophosphamide-activating cells - PharmaCyte Biotech; Encapsulated ifosfamide-activating cells - PharmaCyte Biotech; Encapsulated-cell-therapy-PharmaCyte-Biotech; Microencapsulated-P450-2B1-expressing-cells-PharmaCyte-Biotech; NovaCaps®; Ovarian cancer cell therapy - PharmaCyte Biotech; P450-2B1-gene-therapy-PharmaCyte-Biotech; Pancreatic cancer cell therapy - PharmaCyte Biotech

Latest Information Update: 14 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bavarian Nordic; GSF-National Research Center for Environment and Health
  • Developer PharmaCyte Biotech; Translational Drug Development
  • Class Cell therapies; Cyclophosphamides; Gene therapies; Oxazines
  • Mechanism of Action Cell replacements; Cytochrome P-450 enzyme system stimulants; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Breast cancer; Malignant ascites; Ovarian cancer
  • Research Pain

Most Recent Events

  • 20 May 2019 PharmaCyte Biotech intends to file an IND application with the US FDA for Pancreatic cancer (Inoperable/Unresectable, Late-stage disease)
  • 26 Mar 2018 PharmaCyte Biotech files a patent protection with the United States Patent and Trademark Office for microencapsulated CYP 2B1-expressing cells
  • 06 Feb 2018 PharmaCyte plans to file an IND application with the US FDA in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top